Three new publications reviewing drugs used in diabetes are now available online to stakeholders

28th Sep 2018

Two medicines in practice documents review the cardiovascular outcomes associated with the SGLT2 inhibitors, and the GLP1 receptor agonists. These publication are specifically designed to support stakeholder Medicines Management services to maximise health gains through the optimum use of medicines by influencing and changing prescribing behaviour. Additionally, a new drug evaluation of Semaglutide in the treatment of type 2 diabetes provides a concise, structured evaluation of the efficacy, safety, cost and potential place in therapy for this new GLP1 receptor agonist.